<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patnaree Wongmanit</style></author><author><style face="normal" font="default" size="100%">Kusuma Sriyakul</style></author><author><style face="normal" font="default" size="100%">Parunkul Tungsukruthai</style></author><author><style face="normal" font="default" size="100%">Ouppatham Supasyndh</style></author><author><style face="normal" font="default" size="100%">Pratya Phetkate</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renal Resistive Index and Estimated Glomerular Filtration Rate in Nondiabetic Chronic Kidney Disease Stage 3: A Cross-Sectional Analytical Study</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">538-544</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Renal resistive index (RRI) and estimated glomerular filtration rate (eGFR) are predictive markers for chronic kidney disease (CKD) progression. &lt;strong&gt;Aim:&lt;/strong&gt; To evaluate RRI value, eGFRcr-cys and renal biomarker in nondiabetic patients with CKD stage 3 in Bangkok, Thailand. &lt;strong&gt;Methods:&lt;/strong&gt; A cross-sectional analytical analysis was conducted involving nondiabetic patients with CKD stage 3, aged 35-85 years. Ultrasound was used to assess the RRI of arteries in both kidneys. Patients underwent assessments of serum and urine 24-hour. &lt;strong&gt;Results:&lt;/strong&gt; Among the 61 participants (67.2% male; mean age 69.03 ± 12.59 years), the mean eGFRcr-cys was 41.63 ± 8.64 mL/min/1.73 m², and the mean RRI was 0.65 ± 0.06. Patients were categorized into three RRI groups: low (&amp;lt;0.65, n=35), intermediate (0.65-0.70, n=14), and high (&amp;gt;0.70, n=12). The high RRI group showed a mean RRI of 0.73 ± 0.05 (p &amp;lt; 0.01). Among those with high RRI group were significant decreased right kidney size (p&amp;lt;0.05) and they had a lower BMI, averaging 22.49 ± 3.48. An increase in PP (59.66 ± 13.84, p=0.04) was also significant in this group. The correlations coefficient of RRI value showed a significant positive correlation with age (p&amp;lt;0.05) and significant negative with BMI (p&amp;lt;0.05). In addition, eGFRcr-cys displayed a significant negative correlation with UAGT and 24hUP (p&amp;lt;0.05) and a significant while eGFRcr-cys positive correlation with both kidney size and urine iNOS(p&amp;lt;0.01). &lt;strong&gt;Conclusion:&lt;/strong&gt; An increase in RRI is inversely linked to age, BMI, and PP. Lower eGFR is correlated with factors that cause CKD progression.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">538</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Patnaree Wongmanit&lt;sup&gt;1&lt;/sup&gt;, Kusuma Sriyakul&lt;sup&gt;1&lt;/sup&gt;, Parunkul Tungsukruthai&lt;sup&gt;1&lt;/sup&gt;, Ouppatham Supasyndh&lt;sup&gt;2&lt;/sup&gt;, Sucharat Tungsukruthai&lt;sup&gt;3&lt;/sup&gt;, Pratya Phetkate&lt;sup&gt;1&lt;/sup&gt;*&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Integrative Medicine, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, 12120, THAILAND.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Faculty of Medicine, Kasetsart University, Ngamwongwan Rd, Chatuchak, Bangkok 10900, THAILAND.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90110, THAILAND.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patnaree Wongmanit</style></author><author><style face="normal" font="default" size="100%">Parunkul Tungsukruthai</style></author><author><style face="normal" font="default" size="100%">Pratya Phetkate</style></author><author><style face="normal" font="default" size="100%">Daraporn Rungprai</style></author><author><style face="normal" font="default" size="100%">Sucharat Tungsukruthai</style></author><author><style face="normal" font="default" size="100%">Ouppatham Supasyndh</style></author><author><style face="normal" font="default" size="100%">Kusuma Sriyakul</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Safety Assessment of Supplementation with Cymbopogon citratus Stapf. (Lemongrass) Extract in Patients with Chronic Kidney Disease Stage 3: A Preliminary 90-Days Prospective Study</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Chronic Kidney Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">CKD stage 3</style></keyword><keyword><style  face="normal" font="default" size="100%">Cymbopogon citratus Stapf.</style></keyword><keyword><style  face="normal" font="default" size="100%">Lemongrass</style></keyword><keyword><style  face="normal" font="default" size="100%">Safety</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">976-986</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Chronic kidney disease is a major public health issue, and due to resource constraints, many can't access dialysis. &lt;em&gt;C. citratus&lt;/em&gt;, lemongrass is globally prevalent and known to increase urine output without toxicity.&lt;strong&gt; Objective:&lt;/strong&gt; To examine the safety of &lt;em&gt;C. citratus&lt;/em&gt; in patients with CKD stage 3. &lt;strong&gt;Materials and Methods:&lt;/strong&gt; The major compound of &lt;em&gt;C. citratus&lt;/em&gt; was analyzed using high-performance liquid chromatography (HPLC). 64 patients were enrolled and randomly assigned to control or &lt;em&gt;C. citratus&lt;/em&gt; groups. The control group received a placebo, whereas the &lt;em&gt;C. citratus&lt;/em&gt; group received 900 mg of &lt;em&gt;C. citratus&lt;/em&gt; daily for 90 days. All participants were examined BUN, Scr, Cys-C, and eGFR, liver functions, RBC, HCT, Na+, K+, Cl-, and HCO3, and other biochemical parameters. &lt;strong&gt;Results:&lt;/strong&gt; HPLC showed &lt;em&gt;C. citratus&lt;/em&gt; contains of phenolic compounds. Clinically, &lt;em&gt;C. citratus &lt;/em&gt;group had no notable side effects on T-Bil, AST, ALT and ALP. Also, maintained eGFR, SCys-C, K+ and Cl level. The level of blood Na+ was significant increase at day 30 (p &amp;lt; 0.05). The control group had a significant decrease in eGFR and HCO3 levels (p &amp;lt; 0.05) and a significant increase of Cl- and SCys-C. In addition, no statistical differences had found between groups in eGFR, BUN, Cr, Na&lt;sup&gt;+&lt;/sup&gt;, K&lt;sup&gt;+&lt;/sup&gt;, HCO3, PO4, RBC and HCT levels. Throughout the 90 days, no drug allergies or side effects were reported. &lt;strong&gt;Conclusion:&lt;/strong&gt; Dietary supplementation with &lt;em&gt;C. citratus&lt;/em&gt; may have a favorable effect on delaying the course of CKD and is safe to use for patients with CKD stage 3.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">976</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Patnaree Wongmanit&lt;sup&gt;1&lt;/sup&gt;, Parunkul Tungsukruthai&lt;sup&gt;1&lt;/sup&gt;, Pratya Phetkate&lt;sup&gt;1&lt;/sup&gt;, Daraporn Rungprai&lt;sup&gt;2&lt;/sup&gt;, Sucharat Tungsukruthai&lt;sup&gt;3&lt;/sup&gt;, Ouppatham Supasyndh&lt;sup&gt;4&lt;/sup&gt;, Kusuma Sriyakul&lt;sup&gt;1,&lt;/sup&gt;*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Integrative Medicine, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, 12120, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Faculty of Pharmacy, Silpakorn University (Sanamchandra Palace Campus), Nakhon Pathom, 73000, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90110, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Faculty of Medicine, Kasetsart University, Chatuchak, Bangkok 10900, THAILAND.&lt;/p&gt;
</style></auth-address></record></records></xml>